Skip to main content
Top
Published in: Annals of Hematology 5/2021

01-05-2021 | Imatinib | Letter to the Editor

Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion

Authors: Mirei Horiuchi, Masahiro Yoshida, Kai Yamasaki, Ryoko Sakagami, Takane Aoyama, Naoko Tatsumi, Minako Tsutsumi, Yosuke Nakaya, Hoyuri Fuseya, Takuro Yoshimura, Yoshiki Hayashi, Takafumi Nakao, Takahisa Yamane

Published in: Annals of Hematology | Issue 5/2021

Login to get access

Excerpt

Dear Editor, …
Literature
1.
go back to reference Hayakawa F, Sakura T, Yujiri T et al (2014) Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan adult leukemia study group. Blood Cancer J 4:e252CrossRef Hayakawa F, Sakura T, Yujiri T et al (2014) Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan adult leukemia study group. Blood Cancer J 4:e252CrossRef
2.
go back to reference Roberts KG, Li Y, Payne-Turner D et al (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371:1005–1015CrossRef Roberts KG, Li Y, Payne-Turner D et al (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371:1005–1015CrossRef
3.
go back to reference Kantarjian HM, O'Brien S, Smith TL et al (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547–561CrossRef Kantarjian HM, O'Brien S, Smith TL et al (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547–561CrossRef
4.
go back to reference Roberts KG, Morin RD, Zhang J, Hirst, et al. (2012) Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22:153–166CrossRef Roberts KG, Morin RD, Zhang J, Hirst, et al. (2012) Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22:153–166CrossRef
5.
go back to reference Welsh SJ, Churchman ML, Togni M, Mullighan, et al. (2018) Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis. Leukemia 32:38–48CrossRef Welsh SJ, Churchman ML, Togni M, Mullighan, et al. (2018) Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis. Leukemia 32:38–48CrossRef
6.
go back to reference Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E (2013) Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica 98:e146–e148CrossRef Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E (2013) Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica 98:e146–e148CrossRef
7.
go back to reference Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, Wragg C, Moppett J, Cummins M, Tunstall O, Parker CA, Saha V, Goulden N, Vora A, Moorman AV, Harrison CJ (2016) EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 127:2214–2218CrossRef Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, Wragg C, Moppett J, Cummins M, Tunstall O, Parker CA, Saha V, Goulden N, Vora A, Moorman AV, Harrison CJ (2016) EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 127:2214–2218CrossRef
8.
go back to reference Weston BW, Hayden MA, Roberts KG, Bowyer S, Hsu J, Fedoriw G, Rao KW, Mullighan CG (2013) Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 31:e413–e416CrossRef Weston BW, Hayden MA, Roberts KG, Bowyer S, Hsu J, Fedoriw G, Rao KW, Mullighan CG (2013) Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 31:e413–e416CrossRef
9.
go back to reference Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR, Children's Oncology Group (2009) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470–480CrossRef Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR, Children's Oncology Group (2009) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470–480CrossRef
10.
go back to reference Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M, for the TRANSCALL Consortium, the International BFM Study Group (2018) IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol 36:1240–1249CrossRef Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M, for the TRANSCALL Consortium, the International BFM Study Group (2018) IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol 36:1240–1249CrossRef
Metadata
Title
Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion
Authors
Mirei Horiuchi
Masahiro Yoshida
Kai Yamasaki
Ryoko Sakagami
Takane Aoyama
Naoko Tatsumi
Minako Tsutsumi
Yosuke Nakaya
Hoyuri Fuseya
Takuro Yoshimura
Yoshiki Hayashi
Takafumi Nakao
Takahisa Yamane
Publication date
01-05-2021
Publisher
Springer Berlin Heidelberg
Keyword
Imatinib
Published in
Annals of Hematology / Issue 5/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-04332-8

Other articles of this Issue 5/2021

Annals of Hematology 5/2021 Go to the issue